Dicks Sporting Goods Inc vs Mesoblast Limited — how do they compare? Dicks Sporting Goods Inc trades at $134.99 (market cap $13.26B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Dicks Sporting Goods Inc is far larger — about 7.6× Mesoblast Limited's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Mesoblast Limited for 14 Days on average.
| DKS | MESO | |
|---|---|---|
Market Cap | $13.26B | $1.75B |
Volume | 2,292,035 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $20.96 |
52-Week Low | $121.15 | $13.19 |
Typical Hold Time | 19 Days | 14 Days |
Enterprise Value | $20.31B | $1.83B |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, amid a bearish technical signal and ongoing securities class action news. The stock shows mixed fundamentals with a trailing P/E of 14.86 and P/S of 0.57, while recent earnings beat estimates in two of the last three quarters. Revenue grew to $13.44B in 2025, though net income margin compressed to 3.97% in 2026 trends. Analyst consensus remains positive with a $153.30 price target and 57% buy ratings, but legal overhangs and a negative cash flow trend present headwinds.
The investment case balances attractive valuation multiples against significant litigation risks and weakening profitability. Upside exists if the company navigates legal challenges and stabilizes margins, but the bearish technical setup and negative investor sentiment suggest caution. The stock's near-term direction will likely hinge on Q3 2026 earnings results and developments in the class action lawsuit.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Trailing returns across standard periods
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →